ImmunityBio Announces FDA Approval of ANKTIVA, First-in-Class IL-15 Receptor Agonist for…
ImmunityBio, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved ANKTIVA (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for…
Read More...
Read More...